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Recently, we and other groups revealed that gain-of-function mutations in the human ether à go-
go voltage-gated potassium channel hEAG1 (Kv10.1) lead to developmental disorders with 
associated infantile-onset epilepsy. However, the physiological role of hEAG1 in the central 
nervous system remains elusive. Potent and selective antagonists of hEAG1 are therefore much 
sought after, both as pharmacological tools for studying the (patho)physiological functions of this 
enigmatic channel and as potential leads for development of anti-epileptic drugs. Since animal 
venoms are a rich source of potent ion channel modifiers that have been finely tuned by millions 
of year of evolution, we screened 108 arachnid venoms for hEAG1 inhibitors using 
electrophysiology. Two hit peptides (Aa1a and Ap1a) were isolated, sequenced, and chemically 
synthesised for structure-function studies. Both of these hEAG1 inhibitors are C-terminally 
amidated peptides containing an inhibitor cystine knot motif, which provides them with 
exceptional stability in both plasma and cerebrospinal fluid. Aa1a and Ap1a are the most potent 
peptidic inhibitors of hEAG1 reported to date, and they present a novel mode of action by 
targeting both the activation and inactivation gating of the channel. These peptides should be 
useful pharmacological tools for probing hEAG1 function as well as informative leads for the 





Voltage-gated potassium (KV) channels promote K
+ efflux upon membrane depolarization in 
excitable cells, thereby helping to restore the resting membrane potential. The human ether á go-
go channel (hEAG1, also known as KV10.1 and KCNH1), encoded by the KCNH1 gene, is a member 
of the KV channel family. Although EAG1 channels contain several intracellular domains, they 
adopt a classical homotetrameric KV channel architecture, with each of the four subunits 
containing six membrane-spanning α-helices (S1–S6). Helices S1–S4 serve as voltage sensor units, 
while the S5–S6 helices from each subunit come together to form the channel pore [1, 2]. 
EAG1 mediates rapid, potassium-selective, non-inactivating outward currents upon membrane 
depolarization [2, 3]. The channel is preferentially expressed in the central nervous system (CNS), 
with high abundance in the olfactory bulb, cerebral cortex, hippocampus, hypothalamus and 
cerebellum [4]. However, the neurophysiological role of EAG1 remains elusive, in part due to the 
lack of selective inhibitors [2]. Recently, de novo heterozygous KCNH1 mutations were reported in 
patients with developmental disorders and infantile-onset epilepsy, including Temple–Baraitser 
syndrome [5] and Zimmermann–Laband syndrome [6]. 
Under normal circumstances, expression of KCNH1 is barely detectable outside the CNS, but the 
channel is robustly overexpressed in a variety of human tumours of variable tissue origin, 
including liver, prostate, ovary, colon, thyroid, skin and bone cancers [7-9]. Moreover, 
overexpressson of KCNH1 correlates with poor prognosis for sarcoma, colon cancer, ovary 
carcinoma and acute myeloid leukemia [10]. Subcutaneous injection of KCNH1-transfected cells 
into immunodeficient mice results in invasive tumor development and progression [11].  
Given the important role of hEAG1 in neurodevelopment and tumorigenesis, hEAG1 inhibitors 
might have therapeutic potential. Unfortunately, currently available blockers of hEAG1, such as 
imipramine and astemizole, have either low potency or poor specificity, particularly over the 
closely related hERG (KV11.1) channel [12]. The venoms of spiders and other venomous 
invertebrates evolved to target the nervous system of prey and predators and consequently they 
are highly enriched with ion channel modifiers [13]. Indeed, a peptidic inhibitor of hEAG1 was 
recently isolated from sea anemone venom [14]. Here we used two-electrode voltage-clamp 
(TEVC) electrophysiology to screen a panel of arachnid venoms for inhibitors of hEAG1. We 
identified two disulfide-rich spider-venom peptides that potently inhibit hEAG1. Both peptides 
contain an inhibitor cystine knot (ICK) motif [15] and are highly stable in biological fluids. In 
contrast to most venom-derived KV channel inhibitors, these peptides are gating modifiers rather 
than pore blockers. One of these peptides (Ap1a) is the first reported hEAG1 inhibitor that has 
  
 4 
both high potency (IC50 236 nM) and >30-fold selectivity over hERG, and hence it should be a 
useful pharmacological tool for studying hEAG1 function. 
 
2. Methods and Materials 
2.1 Chemicals 
All chemicals used in this study were from Sigma-Aldrich (Castle Hill, NSW, Australia) unless 
otherwise stated. 
 
2.2 Screen of arachnid venoms against hEAG1 using TEVC electrophysiology 
An in-house collection of 108 arachnid venoms (63 spider and 45 scorpion venoms, Table 1) was 
screened for activity against hEAG1. Spider venoms were obtained by electrostimulation, whereas 
scorpion venoms were mainly obtained by aggravation, sometimes assisted by additional 
electrostimulation. Venom was collected, lyophilised and stored at –80°C until required. Venoms 
and venom fractions were assessed against hEAG1 heterologously expressed in Xenopus oocytes. 
Briefly, the hKCNH1-pcDNA3.1 plasmid [5] was linearized, then capped cRNAs were synthesized 
using a T7 mMESSAGE-mMACHINE transcription kit (Thermo Fisher Scientific Australia, Scoresby 
VIC, Australia). Stage V-VI oocytes were harvested from ovarian lobes of anesthetised Xenopus 
laevis frogs (University of Queensland Animal Ethics Approval QBI/AIBN/087/16) and 
defolliculated by treatment with collagenase type I. Oocytes injected with 20 ng of hKCNH1 cRNA 
were incubated for 24 h at 17°C in ND96 solution (96 mM NaCl, 2 mM KCl, 1 mM CaCl2, 2 mM 
MgCl2, 5 mM HEPES, pH 7.4), supplemented with 2.5 mM sodium pyruvate, 50 g/ml gentamicin 
and 2.5% horse serum (Thermo Fisher Scientific) prior to electrophysiological recordings. TEVC 
recordings were made at room temperature (20–22°C) using an Axoclamp 900A amplifier 
(Molecular Devices, San Jose, CA, USA). Standard borosilicate microelectrodes used for recording 
had resistance of 0.5–1 M when filled with 3 M KCl solution. Stimulation, data acquisition, and 
analysis were performed using pCLAMP 10 software (Molecular Devices). Oocytes were clamped 
at –120 mV and outward currents elicited by a 50-ms depolarising steps to +80 mV every 10 s.  
 
2.3 Isolation of hEAG1 inhibitors from spider venoms 
Lyophilised venom (1 mg) was diluted with 5% solvent B (90% acetonitrile (ACN), 0.05% trifluoro-
acetic acid (TFA) in H2O) and loaded onto an analytical C18 reversed-phase (RP) HPLC column 
(Aeris Widepore 3.6 µm; Phenomenex Australia, Lane Cove, NSW, Australia) attached to a 
Prominence HPLC system (Shimadzu Scientific Instruments, Rydalmere, NSW, Australia). 
Components were eluted at 0.7 ml/min with solvent A (99.95% H2O, 0.05% TFA) and solvent B 
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using isocratic elution at 5% solvent B for 5 min, followed by a gradient of 5–20% solvent B over 5 
min, then 20–40% solvent B over 40 min, and 40–80% solvent B over 5 min. hEAG1-active 
fractions were further fractionated using a Hypersil C18 column (150  4.6 mm; Thermo Fisher 
Scientific Australia) or a Pursuit 3 Diphenyl column (150  3.0 mm, 3 m, 200 Å pore size; Agilent 
Technologies Australia, Mulgrave, VIC, Australia). Absorbance was measured at 214 and 280 nm 
using a Shimadzu Prominence SPD-20A detector. 
 
2.4 Sequencing of peptidic hEAG1 inhibitors 
Peptide masses were determined using matrix-assisted laser desorption/ionization time-of-flight 
mass spectrometry (MALDI-TOF MS) using a Model 4700 Proteomics Analyser (Applied 
Biosystems/Thermo Fisher Scientific, Waltham, MA, USA). -Cyano-4-hydroxycinnamic acid 
(CHCA) was used as matrix. RP-HPLC fractions were mixed 1:1 (v/v) with CHCA (7.5 mg/ml in 1:1 
ACN/H2O, 0.1% TFA) on a MALDI plate. MALDI–TOF spectra were collected in reflector positive 
mode, and reported masses are monoisotopic M+H+ ions. N-terminal Edman sequencing was 
performed by the Australian Proteome Analysis Facility and this data was complemented by MS 
analysis of carboxypeptidase Y-digested peptides to obtain complete peptide sequences. Briefly, 
reduced and alkylated peptides were dissolved in 100 mM ammonium acetate (pH 5.5) and 
digested with 2 ng/µl sequencing-grade carboxypeptidase Y. The digestion at 37°C was stopped at 
1, 2, 5, 10, 15, 30 or 60 min by addition of formic acid (FA) to a final concentration of 0.1%.           
C-terminal sequences were resolved by MS analysis of the digestion products. 
 
2.5 Chemical synthesis of hEAG1 inhibitors 
hEAG1-active peptides were assembled on a Symphony automated peptide synthesiser (Protein 
Technologies, Manchester, UK) on Fmoc-Rink amide (loading 0.80 mmol/g) polystyrene resin at 
0.1 mmol scale. Fmoc deprotection was achieved using 30% piperidine/N,N-dimethylformamide 
(DMF) (1  1.5 min, then 1  3 min). Couplings were performed in DMF using five equivalents of 
Fmoc-amino acid/O-(1H-6-chlorobenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluoro-
phosphate (HCTU)/N,N-diisopropylethylamine (DIEA) (1:1:1) relative to resin loading (1  4 min, 
then 1  8 min). Amino acid side-chains were protected as follows: Asp(OtBu), Arg(Pbf), Cys(Trt), 
Glu(OtBu), His(Trt), Lys(Boc), Ser(tBu), Thr(tBu) and Trp(Boc). Cleavage from the resin and 
removal of side-chain protection was achieved by treatment with 94% TFA/3% triisopropylsilane 
(TIPS)/3% H2O at room temperature for 2 h. After most of the cleavage solution was evaporated 
under a stream of N2, the products were precipitated and washed with cold diethyl ether and 
lyophilised from 50% ACN/0.1% TFA/H2O. The crude products were purified by preparative HPLC. 
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ESI-MS (m/z): Ap1a calc. (avg) 1410.6 [M+3H]3+, found 1410.4; Aa1a calc. (avg) 1386.6 [M+3H]3+, 
found 1386.5. 
 
Solvents for RP-HPLC consisted of 0.05% TFA/H2O (solvent C) and 90% ACN/0.043% TFA/H2O 
(solvent D). Analytical RP-HPLC was performed on a Shimadzu LC20AT system using a Hypersil 
GOLD 2.1  100 mm C18 column (Thermo Fisher Scientific Australia) heated to 40 C with flow 
rate 0.3 ml/min. A gradient of 10–55% solvent D over 30 min was used, with detection at 214 nm. 
Preparative RP-HPLC was performed on a Vydac 218TP1022 column (Grace, Columbia, MD, USA) 
using a flow rate of 16 ml/min and a gradient of 5–45% solvent D over 40 min. MS was performed 
on an API150 mass spectrometer (AB SCIEX Australia, Mulgrave, VIC, Australia) in positive ion 
mode. 
 
Oxidative folding of peptides was achieved by mixing purified reduced peptide (1 equiv), reduced 
glutathione (100 equiv.) and oxidised glutathione (10 equiv.) in 6 M GnHCl (1 ml/mg peptide); this 
mixture was then added to a solution of 1.55 M GnHCl/0.37 M NH4OAc (pH 8.0, 9  volume of 
peptide solution) and stirred at 4C with exposure to air for 2 days. The single major product was 
isolated by preparative RP-HPLC. ESI-MS (m/z): Ap1a calc. (avg) 1408.6 [M+3H]3+, found 1408.5; 
Aa1a calc. (avg) 1384.6 [M+3H]3+, found 1384.5. 
 
2.6 Cell culture 
CHO-K1 cells stably expressing hEAG1 (hEAG1-CHO cells, generously donated by Prof. Steve 
Petrou, The University of Melbourne, Australia) were cultured in F-12 medium supplemented 
with 10% fetal bovine serum (FBS), 2 mM L-glutamine and 100 µg/ml hygromycin. HEK293 cells 
stably expressing the human voltage-gated sodium (NaV) channel hNav1.2, hNav1.5 or hNav1.7 
channels along with the 1 subunit (SB Drug Discovery, Glasgow, UK) were cultured in DMEM 
medium supplemented with 10% FBS, 2 mM L-glutamine, and variable concentrations of 
blasticidin and geneticin, according to the manufacturer’s instructions. Cells were maintained at 
37°C in a humidified 5% CO2 incubator and they tested negative for mycoplasma. HEK293- and 
CHO-based cells have doubling times of about 32 h and 15 h, respectively, under the above 
culture conditions. Cells used for patch-clamp electrophysiology were of passage number 10–20. 
 
2.7 Patch-clamp electrophysiology 
Patch-clamp experiments were conducted at room temperature in the whole-cell configuration 
using an Axon MultiClamp 700B amplifier (Molecular Devices) or a QPatch 16X automated 
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platform (Sophion Bioscience, Ballerup, Denmark). Cells were continuously superfused with bath 
solution containing 140 mM NaCl, 2.5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 8 mM glucose and 10 
mM HEPES, adjusted to pH 7.4 with NaOH. Patch pipettes were pulled from borosilicate glass and 
typically had a resistance of 2–5 MΩ when filled with an internal solution containing 70 mM KF, 
60 mM KCl, 15 mM NaCl, 5 mM EGTA-Na and 5 mM HEPES, adjusted to pH 7.2 with NaOH. The 
same bath solution and internal solution were used for all patch-clamp recordings. Series 
resistance did not exceed 5 MΩ and was 70–80% compensated. Acquired currents were filtered 
at 1 kHz, sampled at 10 kHz, collected and analysed using Clampex 10.0 software (Molecular 
Devices) or QPatch Assay software 5.2 (Sophion Bioscience). 
 
To quantify the inhibitory potency of peptides, hEAG1/hERG currents elicited by a depolarisation 
to +80 mV for 240 ms were recorded with increasing concentrations of peptide. For Nav channels, 
currents were triggered at 0 mV for 50 ms. Concentration-response relationships were fitted with 
the Hill equation: 
  
    
 
    
    
      
 
 
where Ix is the steady-state hEAG1/hERG current or peak Nav channel current in the presence of 
peptide at concentration [x], Imax is the current in the absence of peptide, IC50 is the peptide 
concentration at which inhibition was half-maximal, and n is the slope. All values are given as 
mean ± standard deviation (SD) for the number of biologically independent measurements 
indicated (n). Statistical significance was determined using a student’s t-test. 
 
To test the voltage-dependent activation of hEAG1 channels, 1-s pulses from −100 mV to +120 
mV in 10-mV steps were used to activate the channel from a holding potential of −120 mV, 
followed by a 400-ms step to −100 mV. Currents elicited by the test pulse were normalized to Imax, 
plotted against the test voltage, and fitted to a single-Boltzmann function: 
 
 
    
 
 
    
  
  
         
 
 
where I/Imax is the normalized current, z is the equivalent gating charge, Vhalf is the half-activation 
voltage, and F is Faraday’s constant. 
 
Deactivation of hEAG1 was studied by first activating the channel at +80 mV for 800 ms and then 
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deactivating the channel at −140 mV for 500 ms before returning to a holding potential of 
−120 mV. The kinetics of deactivation were analyzed by fitting the deactivation sweep at −140 mV 
with a double-exponential equation;  values were compared using an unpaired t-test with 
Welch's correction. Steady-state inactivation was measured using a three-step protocol: starting 
from a holding potential of −120 mV, pulses were given from −130 mV to +80 mV in 15-mV steps, 
and then the level of inactivation was tested by an activating step at +40 mV. 
 
2.8 Structure determination 
NMR spectroscopy was used to determine the 3D structure of Aa1a. A 300 l sample of Aa1a 
(1 mM in 20 mM sodium phosphate, pH 7.4, 5% D2O) was placed in a susceptibility-matched 
microtube (Sigma-Aldrich), and spectra acquired at 25oC on an Avance 600 MHz spectrometer 
(Bruker BioSpin, Billerica, MA, USA). Resonance assignments were obtained using a combination 
of 2D 1H-1H TOCSY and natural abundance 2D 1H-15N and 1H-13C HSQC spectra. Interproton 
distance restraints were obtained from a 2D 1H-1H NOESY spectrum acquired with a mixing time 
of 250 ms. Spectra were processed using Topspin (v3.2, Bruker) and analysed using CcpNmr 
Analysis v2.4.1 [16]. Chemical shifts, including assignments for 99.5% of protons, were deposited 
in BioMagResBank under accession number 30318. TALOS-N [17] was used to derive dihedral-
angle restraints and the restraint range used in structure calculations was set to twice the 
estimated standard deviation. The 1H-1H NOESY spectrum was manually peak-picked, then the 
torsion angle dynamic package CYANA v3.97 [18] was used to automatically assign the peak list, 
extract distance restraints, and calculate an ensemble of structures. CYANA assigned 92.9% of 
NOESY cross-peaks. 200 structures were calculated based on 523 inter-proton distance restraints, 
9 disulfide-bond distance restraints, and 63 dihedral-angle restraints (Table 2). The 30 structures 
with lowest penalty function values were analysed using MolProbity [19], and the 20 structures 
with highest stereochemical quality were used to represent the structure of Aa1a. The ensemble 
of structures is available from the Protein Data Bank (accession code 5WLX). 
 
2.9 Biological stability of peptides 
The stability of Aa1a and Ap1a was tested by adding the peptides to human cerebrospinal fluid 
(CSF) or human plasma at a final concentration of 2 M and incubating the mixture at 37oC for 
periods up to 72 h (University of Queensland Human Research Ethics Approval 20160008176). De-
identified CSF samples were obtained from patients undergoing lumbar puncture at St. Vincent’s 
Hospital, Sydney, NSW, Australia (Ethics Approval SVH15/024) while male AB plasma was from 
Sigma-Aldrich (Catalog No. H4522). Triplicate samples were collected at each time point, and 
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reaction mixtures precipitated with 5 l of 5% TFA. For each time point, a 0.1 nmol sample was 
processed by LC/MS using a Kinetex C18 column (150 mm × 2.1 mm, particle size 2.6 m, 100 Å 
pore size; Phenomenex) at a flow rate of 0.2 ml/min and a gradient of 2–40% solvent B (90% ACN, 
0.1% FA) in solvent A (0.1% FA) over 14 min coupled with an AB SCIEX 5600 Triple time-of-flight 
(TOF) mass spectrometer (cycle time 0.2751 s). Peptide peak areas were measured at triple-, 
quadruple- and quintuple charge states, and analysed using PeakView and MultiQuant (Applied 
Biosystems/Thermo Fisher Scientific). Human atrial natriuretic peptide (1 M; GenScript, 
Piscataway, NJ, USA) and the analgesic drug Prialt (i.e., -conotoxin MVIIA, 1 M; Alomone Labs, 
Jerusalem, Israel) were used as controls. 
 
3. Results 
3.1 A small number of arachnid venoms contain inhibitors of hEAG1 
We used TEVC electrophysiology to screen arachnid venoms for inhibition of hEAG1. 
Heterologous expression of hEAG1 in Xenopus oocytes generated robust and non-inactivating 
outward K+ currents upon membrane depolarization (Fig. 1). Only 9 of the 108 venoms tested 
(Table 1) inhibited these currents by >50%, and all of these were spider venoms. However, 21 of 
the 63 spider venoms (33%) inhibited hEAG1 to some extent (Table 1), which is similar to the 
proportion of spider venoms (40%) previously reported to contain inhibitors of NaV1.7 [20]. 
 
Venoms from the tarantulas Avicularia aurantiaca and A. purpurea (Fig. 1A) were notable for 
significant inhibition of hEAG1 (Fig. 1B). These venoms were fractionated using RP-HPLC (Fig. 1C), 
then each fraction tested against hEAG1 using the same TEVC protocol. This led to isolation of 
two “hit” peptides with monoisotopic masses of 4148.217 Da and 4220.077 Da as measured using 
MALDI-TOF MS (Fig. 1D and E). Each purified peptide robustly inhibited hEAG1 (Fig. 1F). Based on 
the rational nomenclature proposed for venom peptides [21], these peptides were named -
theraphotoxin-Aa1a (hereafter Aa1a) and /-theraphotoxin-Ap1a (hereafter Ap1a); the  prefix 
denotes inhibition of KV channels, the  prefix denotes inhibition of NaV channels (see below), 
‘theraphotoxin’ indicates the taxonomic family to which these spiders belong, while the genus 
and species are indicated by uppercase and lowercase letters (Aa and Ap, respectively). 
 
3.2 Primary structure of Aa1a and Ap1a 
The amino acid sequences of Aa1a and Ap1a were elucidated by combining data from MS, Edman 
degradation, and amino acid analysis. Edman sequencing revealed the identity of the N-terminal 
35 residues of Aa1a and Ap1a, while MS analysis of peptide digested briefly with 
carboxypeptidase Y indicated that the last amino acid residue is Phe for Ap1a and either Leu or Ile 
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for Aa1a, with both peptides having an amidated C-terminus. Amino acid analysis revealed that 
the C-terminal residue in Aa1a is Ile not Leu. Thus, as shown in Fig. 2A, both peptides consist of 36 
residues, with six cysteines and amidated C-termini. The predicted mass of Aa1a and Ap1a based 
on these sequences (4148.81 Da and 4220.69 Da respectively) matches well with the measured 
mass of the purified native peptides (4148.22 Da and 4220.08 Da respectively). Aa1a and Ap1a 
are clearly paralogues, with 81% identity, but a BLAST search of these sequences against known 
spider toxins in the ArachnoServer database (www.arachnoserver.org; [22, 23] revealed none 
with identity >60%, suggesting that these peptides are novel. The peptide with highest homology 
to Aa1a and Ap1a    (58–59% identity) is U1-theraphotoxin-Gr1b, a toxin with unknown molecular 
target from the Chilean rose tarantula Grammostola rosea [24]. 
 
3.3 Three-dimensional structures of Aa1a and Ap1a 
The C-terminally amidated Aa1a and Ap1a peptides were produced by solid-phase peptide 
synthesis and oxidatively folded in a redox buffer. The synthetic peptides co-eluted on RP-HPLC 
with native peptide isolated from crude venom (Fig. 2B), indicating that they adopt the native 
disulfide-bond architecture. The 3D structure of Aa1a was determined using NMR spectroscopy 
(Fig. 2C). The ensemble of 20 structures is highly precise, with an rmsd of 0.25 ± 0.08 over the 
backbone atoms of residues 3–34, which excludes the flexible N- and C-termini. The ensemble of 
structures has high stereochemical quality, with mean MolProbity score of 1.7 ± 0.1 (Table 2). The 
disulfide-bond connectivity was unequivocally determined from preliminary structure calculations 
performed without disulfide-bond restraints; the intercystine NOEs in the NOESY spectrum [25] 
are consistent with the pattern Cys3-Cys18, Cys10-Cys23 and Cys17-Cys30. The 3D structure of Aa1a 
indicates that the three disulfides form a cystine knot in which the Cys3-Cys18 and Cys10-Cys23 
disulfide bonds and the intervening section of the polypeptide backbone form a closed loop that 
is pierced by the Cys17-Cys30 disulfide. The overall peptide fold conforms to the ICK motif 
commonly adopted by spider toxins [13, 15, 26], with two of the disulfides supporting a canonical 
-hairpin (Fig. 2C). The structure of Ap1a, which differs by only seven residues from Aa1a, is likely 
to be very similar. 
 
Interestingly, most of the hydrophobic residues in Aa1a (F6, L7, W9, W29, W32) are stacked like 
the rungs of a ladder on one face of the peptide (Fig. 2D). These residues are largely conserved in 
Ap1a, where the equivalent residues are F6, W7, W9, W29, and W32 (see alignment in Fig. 2A). 
Hydrophobic patches are often found on the surface of gating-modifier spider toxins where they 




3.4 Aa1a and Ap1a are potent inhibitors of hEAG1 
Ap1a inhibited hEAG1 expressed in CHO cells with an IC50 of 236 ± 21 nM and Hill coefficient of 
1.32 ± 0.13 (Fig. 3B,C; n = 7) as tested by patch-clamp electrophysiology, making it 9-fold more 
potent than imipramine (IC50 1,800 nM; Table 3), the most commonly used hEAG1 inhibitor. Ap1a 
is nearly equipotent with astemizole (IC50 196 nM; Table 3), the most potent known inhibitor of 
hEAG1 [12]. Interestingly, Ap1a does not completely inhibit channel function, with maximum 
inhibition of ~80% at saturating concentrations (Fig. 3C). In contrast, Aa1a is 3-fold less potent 
than Ap1a (IC50 637 ± 59 nM, Hill coefficient 1.03 ± 0.09; n = 5), but at high concentration it 
completely inhibits hEAG1 (Fig. 3A and C).  
 
From raw current traces it is clear that Aa1a and Ap1a have fast on-rates at all concentrations 
tested (Fig. 3A and B). However, they have significantly different off-rates. Whereas Aa1a is easily 
washed off (Fig. 3D), with a calculated off-rate of 19.7 ± 4.2 s (n = 4), the inhibitory effect of Ap1a 
is much less reversible (Fig. 3E), which might partly explain its higher potency. The concentration-
response curves for both peptides have a Hill coefficient of ~1.0 (Fig. 3C), suggestive of a single 
binding site. 
 
3.5 Aa1a and Ap1a are gating-modifiers of hEAG1 
We studied the mechanism of action of Aa1a and Ap1a via patch-clamp of hEAG1-CHO cells. 
Activation of hEAG1 resulted in robust voltage-dependent outward K+ currents with time-
dependent slow inactivation at very positive activating potentials (Fig. 4A, left panel). Fitting the 
activation current-voltage (I-V) relationship data with the Boltzmann equation revealed a half-
maximal activation voltage (V1/2) of 20.8 ± 4.5 mV (n = 14). At concentrations corresponding to 
their IC50 values (i.e., 600 nM Aa1a, 200 nM Ap1a), both peptides caused a significant depolarising 
shift in the I-V relationship for channel activation: V1/2 was shifted to 39.2 ± 4.7 mV (n = 7) and 
37.7 ± 3.1 mV (n = 9), in the presence of Aa1a and Ap1a, respectively (P < 0.0001; Fig. 4A, right 
panel). As a consequence, both peptides significantly reduced channel open probability over the 
physiological membrane potential range. Interestingly, Ap1a, but not Aa1a, promoted voltage- 
and time-dependent slow inactivation of hEAG1 at open state (Fig. 4A, right). 
 
Voltage-gated channels can also be inhibited by enhancing their deactivation. To test this 
possibility, we compared the deactivation of hEAG1 in the presence and absence of 600 nM Aa1a 
or 200 nM Ap1a. As shown in Fig. 4B, the time constant for hEAG1 deactivation (2.4 ± 0.6 ms, n = 
6) was not significantly different from that in the presence of 600 nM Aa1a (3.8 ± 0.8 ms, n = 6) or 
200 nM Ap1a (3.0 ± 0.7 ms, n = 6).  Therefore, neither peptide induced a significant change in 
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deactivation kinetics, indicating that Aa1a and Ap1a do not inhibit hEAG1 by promoting channel 
deactivation. 
 
A characteristic biophysical feature of hEAG1 is that channel activation is dramatically impacted 
by the pre-conditioning membrane potential. Briefly, hEAG1 activation is delayed and slower 
when currents are elicited from more hyperpolarised holding potentials. This phenomenon, which 
is commonly known as the Cole-Moore shift [28], even though this designation is not entirely 
appropriate [2], has been traced to charge movement between early closed states of the channel 
[29, 30]. Interestingly, both peptides significantly enhanced the Cole-Moore shift of hEAG1 
(Fig. 4C, bottom panels). This markedly contrasts with the effect of partial deletion of the EAG 
domain, which almost completely eliminates the dependence of activation kinetics on the holding 
potential (i.e., markedly reduces the Cole-Moore shift; [31]. 
 
With a pre-conditioning membrane potential of –120 mV, the activation kinetics at +40 mV was 
dramatically slowed down by both Aa1a (600 nM) and Ap1a (200 nM); the activation time 
constant () increased from 0.07 ± 0.01 ms (n = 5) in the absence of peptides to 1.69 ± 0.37 ms (n 
= 4) and 1.29 ± 0.18 ms (n = 6) in the presence of Aa1a and Ap1a, respectively (Fig. 4D left). Aa1a 
and Ap1a also shifted the voltage dependence of the initial activation at +40 mV after a long pre-
conditioning step in the depolarising direction, changing V1/2 from –82.1 ± 3.2 mV (n = 5) to –68.0 
± 8.2 mV (n = 6) and  –61.2 ± 8.7 mV (n = 3) respectively (Fig. 4D, middle). Thus, in the presence of 
the peptides, hEAG1 is harder to activate after being exposed to certain pre-conditioning 
membrane potentials within the physiological range. On the other hand, the voltage dependence 
of steady-state inactivation, as measured from the plateaued currents at +40 mV, was largely 
eradicated by the peptides, particularly Aa1a (Figure 4D, right). Aa1a (600 nM) shifted the 
effective V1/2 of steady-state inactivation from –69.8 ± 5.9 mV (n = 4) to 20.5 ± 2.7 mV (n = 3). In 
contrast, 200 nM Ap1a reduced steady-state inactivation magnitude by ~50% without 
significantly changing its voltage dependence (V1/2 = –63.0 ± 5.7 mV, n = 3), further demonstrating 
the functional difference between these peptides despite the high level of sequence identity. 
 
3.6  Aa1a and Ap1a are selective for hEAG1 over hERG 
hERG and hEAG1 are highly homologous members of the same subfamily of EAG-like KV channels. 
hERG is instrumental in repolarisation of the cardiac action potential and consequently inhibition 
of this channel can lead to long QT syndrome and enhanced risk of sudden death [32]. For this 
reason, the FDA mandates that ion channel drug candidates be tested to ensure that that are not 
potent inhibitors of hERG. 
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Thus, to further examine the potential of Ap1a and Aa1a as pharmacological tools for probing 
hEAG1 function, we tested their ability to modulate hERG (Fig. 5A,B). As judged by IC50 levels, 
Aa1a and Ap1a were 13 and 35 times more potent on hEAG1 than on hERG1, respectively (Fig. 
5C). In striking contrast, although astemizole is a good inhibitor of hEAG1 (IC50 196 nM), it is not a 
useful pharmacological tool for selectively probing hEAG1 function because it inhibits hERG with 
>200-fold higher potency (IC50 0.9 nM; Table 3) [33].  
 
A number of spider toxins are promiscuous inhibitors of both KV and NaV channels, and therefore 
we also tested the effects of Aa1a and Ap1a on the human NaV channels hNaV1.2, hNaV1.5 and 
hNaV1.7 which are found in the CNS, heart and peripheral sensory neurons, respectively (Fig. 5). 
Both peptides had about 11-fold selectivity for hEAG1 over NaV1.5, and moderate 2-fold 
selectivity over NaV1.2. However, while Aa1a has about 2-fold selectivity for hEAG1 over Nav1.7, 
Ap1a is approximately equipotent on these channels (Fig. 5C).  
 
3.7 Ap1a and Aa1a are highly stable in serum and CSF 
One of the major concerns for use of peptides in vivo, either as pharmacological tools or drugs, is 
their biological stability. However, the ICK fold typically provides venom peptides with high levels 
of chemical and thermal stability as well as resistance to proteases [26, 34]. Consistent with these 
observations, we found that Aa1a and Ap1a are highly stable in both human serum and CSF (Fig. 
6). Ap1a remained intact after 3 days at 37oC in both fluids, and only 20% of Aa1a was degraded. 
Both peptides were not only much more stable than human atrial natriuretic peptide (hANP) but 
also significantly more resistant to degradation than the analgesic drug ziconotide (ω-conotoxin 
MVIIA), a venom-derived ICK peptide that is administered intrathecally [35] (Fig. 6). 
 
4. Discussion 
Despite abundant hEAG1 expression in the CNS, its neurophysiological role remains unclear [2]. 
hEAG1 has been shown to regulate neurotransmitter release and synaptic transmission [36] and 
gain-of-function mutations in hEAG1 lead to developmental abnormalities and infantile-onset 
epilepsy, such as in Temple-Baraitser and Zimmermann-Laband syndromes [5, 6, 37, 38]. 
Moreover, the KCNH1 gene is predicted to be highly intolerant to functional genetic variation 
[39]. Thus, hEAG1 appears to be intimately involved in fundamental neuronal and developmental 
processes. 
 
In this study we examined arachnid venoms as a potential source of hEAG1 inhibitors that could 
be used to probe the function of this enigmatic channel. We isolated two paralogous spider-
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venom peptides, Aa1a and Ap1a, that inhibit hEAG1 with submicromolar potency. Both peptides 
are significantly more potent than the only two venom peptides previously reported to inhibit 
hEAG1, namely the sea anemone toxin APETx4 (IC50 1,010 nM) and the scorpion toxin -hefutoxin 
(IC50 26 M) (Table 3). Ap1a (IC50 236 nM) is nearly as potent as astemizole, the most potent 
hEAG1 inhibitor described to date (IC50 196 nM). Moreover, whereas Ap1a has advantageous 35-
fold selectivity for hEAG1 over the cardiac channel hERG, astemizole is 200-fold more potent on 
hERG (IC50 0.9 nM; Table 3). Astemizole was introduced in 1977 as a second-generation 
antihistamine but it was subsequently withdrawn from the market as the potent block of hERG by 
both astemizole and its major metabolite desmethylastemizole [33] can lead to potentially fatal 
QT prolongation [32]. Thus, non-selective small molecule hERG/hEAG1 blockers such as 
astemizole have limited therapeutic potential and they are not useful for studying hEAG1 
function. While imipramine is commonly used to study hEAG1 in vitro, it is not a useful in vivo 
probe as it has only 2-fold selectivity over hERG (Table 3). 
 
Ap1a has several other properties that recommend it as a useful tool for studying hEAG1 function 
in vivo. First, it has 11-fold selectivity over the cardiac NaV1.5 channel in addition to its selectivity 
over hERG. Second, Ap1a and Aa1a are both highly stable in human serum and CSF, most likely 
due to their disulfide-rich ICK architecture. Thus, their in vivo half-life is likely to be primarily 
determined by the rate at which they are cleared by the liver and kidneys [40]. 
 
Ap1a does have some potentially undesirable pharmacological properties. It has only 2.2-fold 
selectivity for hEAG1 over NaV1.2, which is primarily located in axon initial segments of excitatory 
neurons in the brain [41], and this might limit its utility for in vivo studies of the CNS population of 
hEAG1. Ap1a is also equipotent on NaV1.7 and hEAG1. NaV1.7 is an analgesic target that is largely 
confined to peripheral sensory neurons [42], and therefore block of this channel in vivo is unlikely 
to be problematic. However, given the promiscuous pharmacology of many venom peptides [43], 
future studies should examine the activity of Ap1a on a wider range of voltage- and ligand-gated 
ion channels.  
 
Ap1a and Aa1a have complex effects on hEAG1 gating. Firstly, they shift the voltage dependence 
of channel activation in a depolarising direction (~20 mV at concentrations corresponding to their 
IC50), which would cause channel open probability to drop by more than 50% during the 
repolarisation phase of the neuronal action potential (Fig. 4A). Although hEAG1 mutations that 
cause infantile-onset epilepsy are widely dispersed throughout the channel, they typically cause a 
hyperpolarising shift in the voltage-dependence of activation [5, 6]. Thus, gating modifiers such as 
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Aa1a and Ap1a that counteract the deleterious effect of these mutations by shifting the 
activation threshold to more depolarised potentials may prove to be better therapeutic 
candidates than pore blockers or gene-knockdown strategies for treating these epileptic 
disorders. 
 
Secondly, Ap1a and Aa1a affect channel inactivation. Unlike hERG channels, which display an 
inward-rectifying I-V relationship due to fast and voltage-dependent C-type inactivation [44, 45], 
mammalian EAG channels are characterised by little or no voltage-dependent inactivation [3, 46]. 
Interestingly, we found that when the membrane was highly depolarised (i.e., potentials > +80 
mV), a voltage- and time-dependent slow inactivation emerged during the activating step in a 
single-pulse protocol (Fig. 4A). This observation supports the hypothesis that hEAG1 channels 
have intrinsic slow inactivation [46], although mouse EAG1 channels do not exhibit this type of 
inactivation [47]. This time-dependent slow inactivation of hEAG1 was not evident at lower 
membrane potentials likely due to its very slow kinetics. Ap1a caused this slow open-state 
inactivation to occur at less depolarised membrane potentials (> +50 mV) and the effect became 
more significant as the membrane potential became more depolarised (Fig. 4A, right). This is 
reminiscent of the significant open-state inactivation of rEAG1 caused by partial [31] or complete 
[48] deletion of the EAG domain, or the inactivation of hEAG1 caused by the binding of 3-nitro-N-
(4-phenoxyphenyl)-benzamide (ICA105574) or a Y464A mutation in the S6 helix [46]. For 
mechanistic reasons that remain to be determined, Aa1a did not affect open-state inactivation of 
hEAG1 in the same manner as Ap1a, which might partially account for its lower potency. 
 
Steady-state inactivation of hEAG1, reported to be 5–10% when tested at +30 mV after a prepulse 
to +20 mV [46], was more significant with the double-pulse protocol used in this study (Fig. 4C,D, 
right). This inactivation was largely countered by Aa1a and Ap1a (Fig. 4D, right). This steady-state 
inactivation appears to be different to the slow open-state inactivation discussed above, as Ap1a 
attenuated the former but promoted the latter, while Aa1a had more significant effects on the 
former than Ap1a, but no effects on the latter (Fig. 4). In this regard, the peptides are different to 
ICA105574, which dramatically promotes both steady-state and open-state inactivation [46]. The 
underlying mechanisms remain to be elucidated, but since the 10- and 12-state Markov models 
built upon experimental data could not exclude the likelihood that hEAG1 can inactivate from any 
state [46], it is possible that the peptides work on different inactivation states that pair with 
different closed or open states.  
 
The proposed binding site for ICA105574 on hEAG1 is located in the pore module between two 
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adjacent subunits of the homotetrameric channel [49]. However, the cryo-EM structure of rEAG1 
[1] revealed two glycosylation sites in the turret area, suggesting that the attached sugar chains 
might surround the extracellular opening to the pore and prevent binding of large toxins. It is 
therefore not surprising that both Aa1a and Ap1a are gating modifiers that likely bind to 
extracellular regions of the voltage sensing domain to exert influence on the pore domain, as 
demonstrated for many other gating modifier toxins [50].  
 
In summary, we isolated and characterised two spider-venom peptides (Aa1a and Ap1a) that 
potently inhibit hEAG1 and have good selectivity over the closely related hERG channel. These 
peptides possess an ICK fold and are highly stable in biological fluids. Along with astemizole, Ap1a 
is the most potent hEAG1 inhibitor reported to date, making it an excellent pharmacological tool 
for studies of this enigmatic channel. It will be interesting in future studies to examine the 
therapeutic potential of these peptides in tumours that ectopically overexpress hEAG1 and in 
epileptic disorders caused by gain-of-function mutations in the channel. 
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Figure 1: Identification of venom peptides that inhibit hEAG1. (A) Crude venoms (5 l) from the 
theraphosid spiders Avicularia aurantiaca and A. purpurea robustly inhibited currents from 
hEAG1 channels expressed in Xenopus oocytes (panel B). (C) Chromatograms resulting from RP-
HPLC fractionation of crude A. aurantiaca and A. purpurea venom using an Aeris Widepore C18 
column (Phenomenex) using a gradient of solvent B (dashed blue line) and a flow rate of 0.7 ml 
min–1. Absorbance was monitored at 214 nm and 280 nm (black and red traces, respectively). 
Fractions were manually collected and screened for hEAG1 inhibition. Fractions found to inhibit 
hEAG1 are shaded gold. (D) Aa1a and Ap1a were purified to homogeneity using a second round of 
separation on either a Hypersil C18 column (Aa1a, left) or a Pursuit 3 Diphenyl C18 column (Ap1a, 
right). (E) MALDI-TOF MS analysis revealed that these venom peptides have monoisotopic masses 
of 4148.217 Da (Aa1a, left) and 4220.077 Da (Ap1a, right). (F) The isolated peptides recapitulated 
the hEAG1 inhibitory activity of the corresponding crude venoms.  
 
Figure 2: Sequence and structure of hEAG1 inhibitors. (A) Sequence alignment of Aa1a and Ap1a, 
with identical residues shaded blue. Disulfide bonds are indicated by orange lines. The secondary 
structure of Aa1a, identified by NMR structural analysis, is shown above the sequences. (B) 
Comparison of RP-HPLC elution times of native and synthetic peptides. Left panel shows 
analytical RP-HPLC chromatograms for elution of synthetic Aa1a, native Aa1a, and a mixture of 
synthetic and native Aa1a. Right panel shows analytical RP-HPLC chromatograms for elution of 
synthetic Ap1a, native Ap1a, and a mixture of synthetic and native Ap1a. Peptides were eluted 
from a Hypersil GOLD C18 column heated to 40°C using a gradient of 10–50% solvent B over 30 
min and a flow rate of 0.3 ml min–1, with detection at 214 nm. (C) Solution structure of Aa1a. 
Overlay of the ensemble of 20 Aa1a structures. β-Strands are coloured cyan and disulfide bonds 
are shown as orange tubes. (D) Ensemble of Aa1a structures showing the ladder of hydrophobic 
residues (F6, L7, W9, W29, and W32) aligned along one face of the peptide. 
 
Figure 3: Potency and reversibility of hEAG1 inhibition by Aa1a and Ap1a. Representative TEVC 
traces showing inhibition of hEAG1 currents by increasing concentrations of (A) Aa1a and (B) 
Ap1a. (C) Fitting of a Hill equation to concentration-response curves for inhibition of hEAG1 
yielded IC50 values of 637 ± 58.6 nM (Hill coefficient 1.0 ± 0.1, n = 5) for Aa1a and 235.8 ± 21 nM 
(Hill coefficient 1.3 ± 0.1, n = 7) for Ap1a. (D,E) Representative traces showing the current changes 
caused by increasing concentrations of peptide, followed by a wash step. The peptide 
concentrations, which are the same as shown in panels A and B, are indicated in units of nM on 
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the figure. The red curve in panel (D) is a single-exponential fit to the wash-out of Aa1a, which 
yielded an off-rate of 19.7 ± 4.2 s (n = 4). Wash out of Ap1a (panel E) was too slow to allow 
estimation of the dissociation rate. 
 
Figure 4: Effect of Aa1a and Ap1a on hEAG1 gating. (A) Left: Representative whole-cell currents, 
obtained using the activation protocol shown in the inset, showing voltage-dependent activation 
of hEAG1 channels expressed in CHO-K1 cells. Right: Activation current-voltage (I-V) relationships 
were built from normalised plateaued currents I/Imax (where I is the current at each test voltage 
and Imax is the maximum current observed for that cell) and fitted with the Boltzmann equation. 
Aa1a (600 nM) and Ap1a (200 nM) shifted the half-activation voltage (V1/2) from 20.8 ± 4.5 mV (n 
= 14) to 39.2 ± 4.7 mV (n = 7) and 37.7 ± 3.1 mV (n = 9), respectively. (B) Left: Deactivation of 
hEAG1 was analyzed using the tail current at –140 mV following an activating pre-pulse to +80 mV 
(left). Right: The time constant of deactivation (tau) was obtained by fitting the deactivation curve 
with a single-exponential function. The time constant for hEAG1 deactivation (2.4 ± 0.6 ms, n = 6) 
was not significantly altered in the presence of 600 nM Aa1a (3.8 ± 0.8 ms, n = 6) or 200 nM Ap1a 
(3.0 ± 0.7 ms, n = 6). (C) Steady-state inactivation of hEAG1 was examined at +40 mV after 10 s 
pre-conditioning steps from –130 mV to +80 mV in 15-mV increments. Representative whole-cell 
currents (left) show the dependence of steady-state inactivation on the pre-conditioning 
membrane potential. The expanded view at right highlights the markedly different activation 
kinetics at +40 mV obtained with different pre-conditioning membrane potentials (Cole-Moore 
shift). The bottom panels are representative whole-cell currents illustrating the effect of the 
peptides on hEAG1 inactivation. (D) The effects of Aa1a and Ap1a on the Cole-Moore shift and 
steady-state inactivation of hEAG1 were reflected by the activation time constants () at +40 mV 
after a –120 mV pre-conditioning step (left) and the I-V relationships at the start (middle) and end 
(right) of the +40 mV activation test pulse. 
 
Figure 5: Effect of Aa1a and Ap1a on hERG and Nav channels. (A,B) Relative potency of of Aa1a 
(panel A) and Ap1a (panel B) on hEAG1, hERG and selected NaV channels (NaV1.2, NaV1.5 and 
NaV1.7) measured using patch-clamp electrophysiology. (C) IC50 values obtained by fitting a Hill 
equation to the concentration-response curves shown in panels A and B (n = 3–8). 
 
Figure 6: Stability of Aa1a (2 µM) and Ap1a (2 µM)  in human CSF (left) and plasma (right) relative 
to human atrial natriuretic peptide (hANP, 1 µM) and the analgesic drug ω-conotoxin MVIIA 




Table 1: List of arachnid venoms screened against hEAG1. 
 SPIDERS (ORDER ARANEAE) 
No. Family Genus Species Sex1 Continent2 hEAG1 activity3 
1 Araneidae Eriophora transmarina F AUS NA 
2 Araneidae Nephila pilipes F AS NA 
3 Atracidae Hadronyche infensa F AUS Inhibitor 
4 Austrochilidae Hickmania troglodytes F AUS Inhibitor 
5 Ctenidae Ancylometes rufus F AM NA 
6 Ctenidae Ancylometes spec. (Guatemala) F AM Inhibitor 
7 Ctenidae Cupiennius salei F AM NA 
8 Ctenidae Phoneutria fera F AM Inhibitor 
9 Ctenidae Phoneutria nigriventer F AM NA 
10 Ctenidae Phoneutria reidyi F AM Agonist 
11 Ctenidae Viridasius fasciatus F AM NA 
12 Dipluridae Diplura spec. (Peru) F AM NA 
13 Dipluridae Linothele fallax F AM Agonist 
14 Dipluridae Linothele megatheloides F AM Inhibitor 
15 Macrothelidae Macrothele gigas F AS NA 
16 Nemesiidae Acanthogonatus francki F AM Inhibitor 
17 Nemesiidae Acanthogonatus pissii F AM Inhibitor 
18 Pisauridae Megadolomedes australianus F AUS Inhibitor 
19 Sparassidae Holconia murrayensis F AUS Agonist 
20 Sparassidae Isopeda villosa F AUS Inhibitor 
21 Sparassidae Neosparassus diana F AUS NA 
22 Sparassidae Polybetes pythagoricus F AM NA 
23 Sparassidae Sparassidae spec (Flores, Indonesia) F AS Agonist 
24 Theraphosidae Acanthoscurria geniculata F AM NA 
25 Theraphosidae Augacephalus ezendami F AF NA 
26 Theraphosidae Avicularia aurantiaca F AM Inhibitor* 
27 Theraphosidae Avicularia cf juruensis F AM Inhibitor* 
28 Theraphosidae Avicularia purpurea F AM Inhibitor* 
29 Theraphosidae Avicularia spec. (Puerto Maldonado, Peru) F AM Inhibitor* 
30 Theraphosidae Avicularia variegata F AM Inhibitor* 
31 Theraphosidae Brachypelma boehmei F AM NA 
32 Theraphosidae Caribena versicolor F AM Inhibitor* 
33 Theraphosidae Ceratogyrus marshalli F AF Agonist 
34 Theraphosidae Chaetopelma olivaceum F AF NA 
35 Theraphosidae Chilobrachys dyscolus F AS NA 
36 Theraphosidae Chromatopelma cyaneopubescens F AF NA 
37 Theraphosidae Coremiocnemis tropix  F AUS NA 
38 Theraphosidae Cyriopagopus hainanus F AS NA 
39 Theraphosidae Encyocratella olivacea F AF Inhibitor 
40 Theraphosidae Heteroscodra maculata F AF NA 
41 Theraphosidae Homoeomma spec. ("blue") F AM NA 
42 Theraphosidae Hysterocrates ederi F AF Inhibitor* 
43 Theraphosidae Hysterocrates gigas F AF NA 
44 Theraphosidae Hysterocrates hercules F AF NA 
45 Theraphosidae Hysterocrates spec (West Cameroon) F AF Inhibitor* 
46 Theraphosidae Lampropelma nigerrimum F AS NA 
47 Theraphosidae Lasiodora klugi F AM NA 
48 Theraphosidae Monocentropus lambertoni F AF NA 
49 Theraphosidae Ornithoctonus aureotibialis F AS Inhibitor 
50 Theraphosidae Orphnaecus spec. ("treedweller") F AS Inhibitor 
51 Theraphosidae Pamphobeteus insignis F AM NA 
52 Theraphosidae Phormingochilus carpenteri F AS Agonist 
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53 Theraphosidae Poecilotheria fasciata F AS NA 
54 Theraphosidae Psalmopoeus cambridgei F AM Agonist 
55 Theraphosidae Pterinochilus murinus F AF NA 
56 Theraphosidae Selenocosmia crassipes  F AUS NA 
57 Theraphosidae Selenotholus cf foelschei  F AUS NA 
58 Theraphosidae Sericopelma spec. (Panama) F AM NA 
59 Theraphosidae Stromatopelma calceatum F AF NA 
60 Theraphosidae Tapinauchenius elenae F AM NA 
61 Theraphosidae Thrixopelma ockerti F AM NA 
62 Theraphosidae Xenesthis spec. ("white", Colombia) F AM NA 
63 Theraphosidae Ybyrapora diversipes F AM Inhibitor* 
SCORPIONS (ORDER SCORPIONES) 
No. Family Genus Species Sex1 Continent2 hEAG1 activity3 
64 Bothriuridae Bothriurus coriaceus U AM Inhibitor 
65 Bothriuridae Bothriurus dumayi U AM Agonist 
66 Bothriuridae Bothriurus keyserlingi U AM Inhibitor 
67 Buthidae Androctonus amoreuxi M AF Agonist 
68 Buthidae Androctonus australis U AF Agonist 
69 Buthidae Androctonus australis "Hector" M AF Inhibitor 
70 Buthidae Androctonus bicolor U AF NA 
71 Buthidae Androctonus crassicauda  U AF Inhibitor 
72 Buthidae Androctonus crassicauda  M AF Inhibitor 
73 Buthidae Androctonus mauritanicus U AF NA 
74 Buthidae Apistobuthus pterygocercus F AF NA 
75 Buthidae Centruroides bicolor U AM NA 
76 Buthidae Hottentotta franzwerneri M AF NA 
77 Buthidae Hottentotta gentili M AS NA 
78 Buthidae Hottentotta jayakari F AF Agonist 
79 Buthidae Hottentotta judaicus F AF NA 
80 Buthidae Hottentotta minusalta F AS NA 
81 Buthidae Hottentotta salei U AF Agonist 
82 Buthidae Leiurus abdullahbayrami M AF Inhibitor 
83 Buthidae Leiurus cf haenggii F AF NA 
84 Buthidae Leiurus hebraeus F AF NA 
85 Buthidae Leiurus quinquestriatus U AF Inhibitor 
86 Buthidae Leiurus spec. (Oman) U AS NA 
87 Buthidae Leiurus spec. ("ullrichi") F AF Agonist 
88 Buthidae Mesobuthus gibbosus U EU NA 
89 Buthidae Parabuthus capensis  M AF Inhibitor 
90 Buthidae Parabuthus mossambicensis F AF Agonist 
91 Buthidae Parabuthus raudus U AF NA 
92 Buthidae Parabuthus schlechteri U AF NA 
93 Buthidae Parabuthus stridulus M AF NA 
94 Buthidae Parabuthus transvaalicus F AF NA 
95 Buthidae Parabuthus villosus U AF NA 
96 Buthidae Parabuthus villosus ("black") M AF NA 
97 Caraboctonidae Hadrurus arizonensis U AM Agonist 
98 Scorpionidae Heterometrus bengalensis U AS Agonist 
99 Scorpionidae Heterometrus cf cyaneus U AS Inhibitor 
100 Scorpionidae Heterometrus cyaneus U AS Agonist 
101 Scorpionidae Heterometrus petersii U AS Agonist 
102 Scorpionidae Heterometrus spinifer U AS NA 
103 Scorpionidae Nebo hierichonticus U AF Inhibitor 
104 Scorpionidae Nebo omanensis F AF Inhibitor 
105 Scorpionidae Nebo whitei F AF NA 
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106 Scorpionidae Opistophthalmus boehmi M AF NA 
107 Scorpionidae Pandinoides cavimanus U AF Agonist 
108 Vaejovidae Paravaejovis hoffmanni U AM Inhibitor 
Footnotes: 1Sex: F, female; M, male; U, unknown; 2Continent: AM, America; AF, Africa; AS, Asia; AUS, Australia; 
3Activity against hEAG1 in TEVC screen: venoms are defined as containing an inhibitor or agonist of hEAG1, or 

















Table 2: Structural statistics for the ensemble of Aa1a structures (PDB ID 5WLX)1 
Experimental restraints 
 
Inter-proton distance restraints  
Total 523 
Intra-residue (i = j)   76 
Sequential (|i - j| = 1) 144 
Medium range (1 < |i – j|  5) 120 
Long range (|i – j|  5) 183 
Disulfide-bond restraints     9 
Dihedral-angle restraints (, )  
Total   63 
 dihedral angle restraints   25 
 dihedral angle restraints   24 
1 angle restraints   14 
Total number of restraints per residue      16.5 
  
Violations of experimental restraints   0 
  
RMSD from mean coordinate structure (Å)  
All backbone atoms   0.74 ± 0.48 
All heavy atoms   0.97 ± 0.42 
Backbone atoms (Residues 3–34)   0.25 ± 0.08 
Heavy atoms (Residues 3–34)   0.62 ± 0.09 
  
Stereochemical quality2  
Residues in most favored Ramachandran region (%) 79.4 ± 3.3 
Residues in disallowed Ramachandran regions (%)   0.0 ± 0.0 
Favorable sidechain rotamers (%) 82.9 ± 5.2 
Unfavorable sidechain rotamers (%)   4.8 ± 1.7 
Clashscore, all atoms3   0.0 ± 0.0 
Overall MolProbity score   1.7 ± 0.1 
  
 
1 All statistics are given as mean ± S.D. 
2 Sterochemical quality according to MolProbity (http://helix.research.duhs.duke.edu). 











Table 3: Pharmacological properties of hEAG1 inhibitors. 
  
IC50 (nM) or extent of channel inhibition (%) 
Ref.3 
hEAG1 hERG KV1.3 KV1.4 KV2.1 NaV1.2 NaV1.4 NaV1.5 NaV1.7 
Small 
molecule 
astemizole 196 0.9 ND
1
 ND ND ND ND ND ND 1,2 
imipramine 1800 3400 ND ND ND ND ND ND ND 1 
Venom 
peptide 
Ap1a 236 8197 ND ND ND 519 ND 2565 222 3 

















2 40000 NE NE ND ND ND ND 5–7 
1ND = not determined; 2NE = no effect; 3References: 1. [12]; 2. [33]; 3. Current study; 4. [14]; 5. [51]. 6. 
[52]. 7. [53]. 
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